Skin care composition and application thereof
Patent Information
- Application Number
- CN202480033257.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-15
- Publication Date
- 2026-01-02
AI Technical Summary
The skin is damaged by environmental pollution, ultraviolet rays, age and other factors, resulting in aesthetics and health problems. Existing skin care products are difficult to effectively solve problems such as whitening, anti-inflammatory, anti-sugar, moisturizing, firming and anti-aging.
Using a skin care composition comprising a first active component such as tetrahydrocurcumin, ergothionine and a second additive component such as tetrahydropiperine, significantly inhibits the activity of inflammatory factors and tyrosinases by synergistically acting, Inhibit the formation of glycosylation end products and enhance skin moisturization and gloss.
Multiple protection of the skin is achieved, which significantly reduces the secretion of inflammatory factors, improves the inhibition rate of tyrosinase and the inhibition rate of glycosylation end products, enhances the moisturizing and gloss of the skin, and improves the firmness and whitening effect of the skin.
Smart Images
Figure CN121263170A_ABST
Abstract
Description
Skin care composition and its application Technical Field
[0001] The present invention belongs to the technical field of cosmetics, and in particular relates to a skin care composition that can be used for whitening, anti-inflammation, anti-sugar, moisturizing, skin firming, antibacterial and / or anti-aging. Background Art
[0002] With the rapid development of society, environmental pollution has become increasingly prominent. Long-term exposure to polluted environments can make the skin vulnerable to damage. Humans face increasing pressure in a fast-paced life. Coupled with the influence of various factors such as ultraviolet rays, age, and drugs, the skin is prone to various problems, which can affect appearance and even cause skin health problems.
[0003] With the continuous development of science and technology and economy, the pursuit of beauty and health has promoted continuous and in-depth research in the field of skin care; people are increasingly interested in skin care compositions and cosmetics that can achieve and improve skin whitening, anti-inflammatory, anti-sugar, moisturizing, skin firming, antibacterial, anti-aging and other effects.
[0004] Summary of the Invention
[0005] In one aspect, the present invention provides a skin care composition comprising a first active component and a second adjunct component.
[0006] In some embodiments, skin care is one or more of: alleviating skin photoaging, reducing fine lines and wrinkles, improving skin elasticity, improving skin firmness, improving skin radiance, brightness or texture, reducing or eliminating acne, alleviating skin inflammation, keeping skin hydrated, and improving or even skin tone. In some embodiments, the skin can be any skin surface selected from the group consisting of the scalp, face, neck, shoulders, back, arms, legs, hands, feet, chest, abdomen, and buttocks.
[0007] In some embodiments, the first active component is selected from one or more of the following: tetrahydrocurcumin, ergothioneine, phloretin, arbutin, resveratrol, vitamin C, dipotassium glycyrrhizate, ceramide, aloe polysaccharide, cactus polysaccharide, astragalus polysaccharide, dendrobium polysaccharide, ginseng polysaccharide, fucoidan, small molecule hyaluronic acid, pearl powder, collagen, tea tree essential oil, thearubigin, salicylic acid, retinol, galactosidone, and carnosine; the second auxiliary component is selected from one or more of the following: tetrahydropiperine, laurocapram, PEG-75 shea butter glycerides, hydrogenated castor oil, glycerin, lauric acid, sucrose laurate, butylene glycol, polysorbate, hydroxyethyl cellulose, 1,2-pentanediol, and ethoxydiglycol. In some embodiments, the first active ingredient can be any suitable active ingredient that can exert whitening, anti-inflammatory, anti-glycemic, moisturizing, skin firming, antibacterial, anti-aging, etc., and the second auxiliary agent component can be any suitable auxiliary agent component that can synergize with the first active ingredient and / or promote the effect of the first active ingredient. In some embodiments, retinol can be replaced with other retinoids selected from tretinoin, isotretinoin, alitretinoin, acitretin, etretinate, adapalene, tazarotene, and their derivatives.
[0008] In some embodiments, the weight ratio of the first active component to the second adjuvant component is 1:20 to 50: 1. In some embodiments, the weight ratio of the first active component to the second adjuvant component can be 1:50 to 100:1, or 1:10 to 20:1.
[0009] In some embodiments, the first active ingredient is selected from one or more of the following: tetrahydrocurcumin, ergothioneine, phloretin, arbutin, resveratrol, vitamin C, dipotassium glycyrrhizate, ceramide, cactus polysaccharide, astragalus polysaccharide, dendrobium polysaccharide, ginseng polysaccharide, thearubigin, retinol, and carnosine.
[0010] In some embodiments, the first active ingredient is selected from one or more of tetrahydrocurcumin and ergothioneine.
[0011] In some embodiments, the second auxiliary agent component is selected from one or more of tetrahydropiperine, laurocapram, hydrogenated castor oil, glycerin, butylene glycol, sucrose laurate, and 1,2-pentanediol. In some embodiments, the second auxiliary agent component is selected from one or more of tetrahydropiperine, laurocapram, and sucrose laurate.
[0012] In some embodiments, the second adjuvant component is selected from one or more of tetrahydropiperine and laurocapram.
[0013] In some embodiments, the first active ingredient is tetrahydrocurcumin and / or ergothioneine, and the second adjuvant ingredient is tetrahydropiperine.
[0014] In some embodiments, the weight ratio of the first active component to the second adjuvant component is 1:2 to 5: 1. In some embodiments, the weight ratio of the first active component to the second adjuvant component can be 1:5 to 10:1, 1:1 to 2:1.
[0015] In some embodiments, the composition of the present invention inhibits tyrosinase activity by about 80%, preferably, by about 85%, or above 90%.
[0016] In some embodiments, the composition of the present invention has an inhibition rate of greater than 20% on TNF-α, IL-6 or IL-8, respectively. Preferably, the inhibition rate on TNF-α secretion can reach about 25%, the inhibition rate on IL-6 can reach about 40%, and the inhibition rate on IL-8 secretion can reach about 55%.
[0017] In some embodiments, the compositions of the present invention can inhibit AGEs by about 50%.
[0018] In some embodiments, the skin care composition is used for whitening, anti-inflammatory, anti-sugar, moisturizing or skin tightening. In some embodiments, the skin care composition can be used for whitening, anti-inflammatory, anti-sugar, moisturizing, skin tightening, antibacterial, anti-aging and other effects.
[0019] In another aspect, the present invention provides a use of the skin care composition as described above in preparing cosmetics.
[0020] In another aspect, the present invention provides a cosmetic comprising the skin care composition as described above.
[0021] In some embodiments, cosmetics include lotions, serums, powders, emulsions, creams, gels, masks, and dressings.
[0022] In some embodiments, the weight ratio of the skin care composition in the cosmetic is 0.1-95%.In some embodiments, the weight ratio of the skin care composition in the cosmetic can be 1-90%, 2-80%, 5-70%, or 10-60%.
[0023] In some embodiments, the skin care composition comprises 20-50% by weight of the cosmetic.
[0024] The composition of the present invention can enable the effective ingredients to cooperate with each other to synergistically exert a greater effect, and is widely used in various skin care and cosmetics. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1. Cytotoxicity of THC, EGT, and THP at different doses (1 μM, 10 μM, 50 μM, and 100 μM).
[0026] Figure 2. Effects of THC, THC+THP, EGT, and EGT+THP on the inflammatory factor TNF-α.
[0027] Figure 3. Effects of THC, THC+THP, EGT, and EGT+THP on the inflammatory factor IL-6.
[0028] Figure 4. Effects of THC, THC+THP, EGT, and EGT+THP on the inflammatory factor IL-8.
[0029] Figure 5. Inhibitory effects of THC, EGT, THC+THP, EGT+THP, and THC+EGT+THP on tyrosinase activity.
[0030] FIG6 . Inhibition rate of the composition in Example 12 on AGEs.
[0031] Figure 7. Propionibacterium acnes colonization results. DETAILED DESCRIPTION
[0032] The preferred embodiments of the present invention will now be described in detail with reference to the embodiments thereof. Although the present invention will be described in conjunction with the preferred embodiments, it should be understood that they are not intended to limit the present invention to these embodiments. On the contrary, the present invention is intended to cover substitutions, modifications and equivalents, which may be included within the spirit and scope of the present invention as defined in the claims. In addition, in the detailed description of the present invention, many specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be apparent to one of ordinary skill in the art that the present invention can be practiced without these specific details. In other cases, well-known methods, procedures, components and other features are not described in detail to avoid unnecessarily obscuring various aspects of the present invention.
[0033] As used herein, the term "or" is intended to include "and" and "or." In other words, the term "or" can also be replaced with "and / or."
[0034] As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0035] As used herein, the term "comprises" or "includes" or variations thereof refers to instances where the term is used in its non-limiting sense, meaning that items following the term are included, but items not specifically mentioned are not excluded. It also includes the more restrictive verbs 'consisting essentially of' and 'consisting of.'
[0036] The composition of the present invention uses a variety of skin care ingredients that can work together to achieve a truly effective effect in combating skin problems.
[0037] Extracted from the Piperaceae family, tetrahydropiperine is a safe and effective natural plant-derived penetration enhancer. It promotes fluidity within the phospholipid bilayer, driving the penetration of active ingredients into cells. Ingredients with similar penetration enhancer or adjuvant properties to tetrahydropiperine and suitable for use in cosmetics include, but are not limited to, laurocapram, PEG-75 shea butter glycerides, hydrogenated castor oil, glycerin, lauric acid, sucrose laurate, butylene glycol, polysorbate, hydroxyethylcellulose, 1,2-pentanediol, and ethoxydiglycol.
[0038] The skin care composition of the present invention is simple and convenient to prepare and can be prepared by simply mixing the raw materials evenly. In some embodiments, the method for preparing the skin care composition of the present invention comprises the following steps: first, evenly mix the raw materials with low content in the raw materials, and then mix them with the raw materials with high content in equal and incremental amounts; more preferably, the raw materials are mixed in a three-dimensional mixing manner, and the mixing time is 20-30 minutes. In some embodiments, the components in the skin care composition of the present invention can be dissolved in a suitable solvent to form a corresponding solution and / or suspension, and then the solutions and / or suspensions of the components are mixed to form a mixed form of the skin care composition of the present invention dissolved in a solvent. In the method for preparing the skin care composition, the components can be reasonably added using a mixing method well known in the art depending on the properties of the raw materials.
[0039] The technical features, implementation methods and beneficial effects of the present invention are further described in detail below in conjunction with specific implementation cases. The embodiments described below are only part of the embodiments of the present invention, not all of the embodiments. Unless otherwise specified, the materials and reagents described in the following examples are all common commercial products and can be purchased on the market.
[0040] Example
[0041] Example 1
[0042] The composition of Example 1 was prepared by mixing ergothioneine, tetrahydropiperine and sucrose laurate in a weight ratio of 1:3:2.
[0043] Example 2
[0044] The composition of Example 2 was prepared by mixing tetrahydrocurcumin, tetrahydropiperine, and hydroxyethyl cellulose in an equal weight.
[0045] Example 3
[0046] The composition of Example 3 was prepared by mixing tetrahydrocurcumin, ergothioneine, tetrahydropiperine, laurocapram and sucrose laurate in a weight ratio of 2:2:3:1:2.
[0047] Example 4
[0048] The composition of Example 4 was prepared by mixing equal weights of tetrahydrocurcumin and tetrahydropiperine.
[0049] Example 5
[0050] The composition of Example 5 was prepared by mixing equal weights of ergothioneine and tetrahydropiperine.
[0051] Example 6
[0052] The composition of Example 6 was prepared by mixing ergothioneine, arbutin, phloretin, tetrahydropiperine, and sucrose laurate in a weight ratio of 3:2:1:3:1.
[0053] Example 7
[0054] The composition of Example 7 was prepared by mixing tetrahydrocurcumin, ergothioneine, resveratrol, glycerol, and laurocapram in a weight ratio of 2:2:1:1:2.
[0055] Example 8
[0056] The composition of Example 8 was prepared by mixing equal weights of tetrahydrocurcumin, ergothioneine and tetrahydropiperine.
[0057] Example 9
[0058] The composition of Example 9 was prepared by mixing equal weights of vitamin C, dipotassium glycyrrhizate, phloretin, ceramide, tetrahydropiperine, and sucrose laurate.
[0059] Example 10
[0060] The composition of Example 10 was prepared by mixing resveratrol, pearl powder, fucoidan, arbutin, and tetrahydropiperine in a weight ratio of 1:2:1:1:2.
[0061] Example 11
[0062] The composition of Example 11 was prepared by mixing tetrahydrocurcumin, retinol, arbutin, dipotassium glycyrrhizate, cactus polysaccharide, tetrahydropiperine, sucrose laurate, and hydroxyethyl cellulose in a weight ratio of 3:2:2:1:2:1:1:1.
[0063] Example 12
[0064] The composition of Example 12 was prepared by mixing ergothioneine, vitamin C, resveratrol, aloe polysaccharide, tetrahydropiperine, and hydroxyethyl cellulose in a weight ratio of 3:3:3:1:1:1.
[0065] Example 13
[0066] The composition of Example 13 was prepared by mixing pearl powder, carnosine, aloe polysaccharide and hydroxyethyl cellulose in a weight ratio of 4:3:1:1.
[0067] Example 14
[0068] The composition of Example 14 was prepared by mixing tetrahydrocurcumin, ergothioneine, carnosine, ceramide, arbutin, laurocapram and polysorbate in a weight ratio of 3:2:1:3:1:1:1.
[0069] Comparative Example
[0070] The comparative examples include compositions containing only the first active ingredient, and existing skin care compositions.
[0071] Performance Testing
[0072] Anti-inflammatory test - testing the anti-inflammatory effect of the composition of the present invention on skin keratinocytes
[0073] The reagents used include: DMED culture medium, fetal bovine serum (FBS), penicillin / streptomycin, MTT cell activity assay kit, cholecalciferol, dimethyl sulfoxide (DMSO), TNF-α assay kit, IL-8 assay kit, IL-6 assay kit, THC (tetrahydrocurcumin), EGT (ergothioneine), THP (tetrahydropiperine), and the compositions of Examples 1-14 of the present invention. The instruments include: a cell culture incubator, a cell counter, and a microplate reader.
[0074] Cell culture: The human normal epidermal keratinocyte (NHEK) cell line HaCat was purchased from Wuhan Saios Biotechnology Co., Ltd. The cells were maintained in a humidified atmosphere (95% air and 5% carbon dioxide, 37°C) and cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, and 1% penicillin / streptomycin. The cultures were harvested and cell morphology was examined using phase contrast microscopy. The cell suspension was counted using a hemocytometer (Marienfeld, Germany) to monitor cell number.
[0075] Cytotoxicity Assay: The MTT assay was used to evaluate the effects of the compositions of the present invention on the viability of normal human epidermal keratinocytes. Briefly, cells were seeded in 96-well plates and treated with the compositions of the examples of the present invention at concentrations of 1 μM, 10 μM, 50 μM, and 100 μM for 72 hours. The cells were then incubated with MTT solution (100 μg / well) for 4 hours. The formazine precipitate was dissolved in dimethyl sulfoxide, and the absorbance at 570 nm was measured using a microplate reader to quantitatively determine the degree of MTT reduction.
[0076] UVB stimulation: Keratinocytes were seeded in 12-well plates (50,000 cells / mL) and cultured to ~80% confluency. Cells were washed once with phosphate-buffered saline (PBS) at room temperature, and 0.5 mL of PBS was added to the cells before UV irradiation. Cells were exposed to 50 mJ / cm² of UV-B (Philips, 311 nm) for 2 minutes. Immediately after irradiation, PBS was replaced with culture medium containing THC (highest non-cytotoxic dose), EGT (highest non-cytotoxic dose), THC (highest non-cytotoxic dose / 2) + tetrahydropiperine (highest non-cytotoxic dose / 2), EGT (highest non-cytotoxic dose / 2) + tetrahydropiperine (highest non-cytotoxic dose / 2), or control (DMSO), and cells were returned to 37°C for 24 hours. Cell culture supernatant was collected and stored at -80°C before use.
[0077] Inflammatory factor detection: Use the reference cytokine samples provided in the kit to generate a standard curve for each cytokine (TNF-α, IL-8, IL-6). The cell culture supernatant is pre-coated with the antibody at the bottom of the microplate, incubated and thoroughly washed. The substrate TMB is used for color development. TMB turns blue under the catalysis of peroxidase and converts to the final yellow under the action of acid. The color depth is positively correlated with the TNF-α, IL-8, and IL-6 in the sample. The absorbance (OD value) is measured at a wavelength of 450nm using a microplate reader, and the sample concentration is calculated according to the standard curve.
[0078] Preparation of tetrahydrocurcumin + tetrahydropiperine test solution: Mix 1 mg / mL THC solution and 1 mg / mL THP solution in a 1:1 ratio. Preparation of ergothioneine + tetrahydropiperine test solution: Mix 1 mg / mL EGT solution and 1 mg / mL THP solution in a 1:1 ratio.
[0079] Figure 1 shows the cytotoxicity of THC, EGT, and THP at different doses (1 μM, 10 μM, 50 μM, and 100 μM). As shown in Figure 1, all doses of the substances were non-toxic to cells, with cell viability around 100% and no less than 85%.
[0080] Figures 2, 3, and 4 show the anti-inflammatory effects of THC, THC + THP, EGT, and EGT + THP on UV-damaged cells, respectively. The results show that in Figure 2, the TNF-α level was approximately 90 pg / ml when treated with THC, and approximately 82 pg / ml when treated with THC + THP. The TNF-α level was approximately 95 pg / ml when treated with EGT, and approximately 80 pg / ml when treated with EGT + THP. These data demonstrate that the combination group effectively inhibits the inflammatory factor TNF-α. In Figure 3, the IL-6 level was 27 pg / ml when treated with THC, and 22 pg / ml when treated with THC + THP. The IL-6 level was 28 pg / ml when treated with EGT, and 23 pg / ml when treated with EGT + THP. These data demonstrate that the combination group effectively inhibits the inflammatory factor IL-6. In Figure 4, the IL-8 level was 25 pg / ml when treated with THC, and 20 pg / ml when THC and THP were used together. The IL-8 level was 23 pg / ml when treated with EGT, and 18 pg / ml when EGT and THP were used together. These data demonstrate that the combined treatments significantly inhibited the inflammatory factor IL-8. Figures 2, 3, and 4 show that THC, THC + THP, EGT, and EGT + THP inhibited the production of inflammatory factors TNF-α, IL-6, and IL-8. THC and EGT exhibited anti-inflammatory effects against UV-damaged cells, and their combination with THP significantly enhanced these anti-inflammatory effects.
[0081] The results showed that the composition of the present invention has a significantly enhanced anti-inflammatory effect on ultraviolet damage to cells. Compared with the inflammatory factors secreted by the control group, the inhibition rate of the composition of the present invention on TNF-α secretion is about 25%, the inhibition rate on IL-6 secretion is about 40%, and the inhibition rate on IL-8 secretion is about 55%.
[0082] Whitening test - testing the inhibitory effect of the composition of the present invention on tyrosinase
[0083] The reagents used include: tyrosinase, tyrosine, potassium chloride, sodium chloride, potassium dihydrogen phosphate, disodium hydrogen phosphate, tetrahydrocurcumin (THC), ergothioneine (EGT), tetrahydropiperine (THP), deionized water, and dimethyl sulfoxide (DMSO). The instruments include: a magnetic stirrer and a microplate reader.
[0084] Reagent preparation: Phosphate buffer solution (PBS): 0.2g potassium chloride, 8g sodium chloride, 0.27g potassium dihydrogen phosphate, 3.58g disodium hydrogen phosphate. First, add 800mL of distilled water and stir with a magnetic stirrer until completely dissolved. Then adjust the pH to 6.8 and make the volume up to 1000mL. After autoclaving, it can be stored at 4°C or at room temperature. 2mM L-tyrosine solution: Weigh 36mg of L-tyrosine and add 100mL of water. Stir on a magnetic stirrer until completely dissolved to obtain the L-tyrosine solution. Preparation of tetrahydrocurcumin test solution: Dissolve 10mg of THC in 10mL of DMSO solution to obtain a 1mg / mL sample solution. Preparation of ergothioneine test solution: Dissolve 10mg of EGT in 10mL of deionized water to obtain a 1mg / mL sample solution. Preparation of Tetrahydropiperine: Dissolve 10 mg of THP in 10 mL of DMSO to obtain a 1 mg / mL sample solution. Preparation of Tetrahydrocurcumin + Tetrahydropiperine Test Solution: Mix 1 mg / mL THC solution and 1 mg / mL THP solution in a 1:1 ratio. Add 1 mL of each to a 5 mL centrifuge tube, invert repeatedly, and shake on a shaker to mix thoroughly. Preparation of Ergothioneine + Tetrahydropiperine Test Solution: Mix 1 mg / mL EGT solution and 1 mg / mL THP solution in a 1:1 ratio. Add 1 mL of each to a 5 mL centrifuge tube, invert repeatedly, and shake on a shaker to mix thoroughly. Preparation of Ergothioneine + Tetrahydrocurcumin + Tetrahydropiperine Test Solution: Mix 1 mg / mL EGT solution, 1 mg / mL THC solution, and 1 mg / mL THP solution in a 1:1 ratio. Add 1 mL of each to a 5 mL centrifuge tube, invert repeatedly, and shake on a shaker to mix thoroughly.
[0085] Add tyrosine solution and sample solution to a 96-well plate in the order shown in the table below and incubate at 30°C for 10 minutes. Then add tyrosinase solution, mix thoroughly, and incubate at 30°C for another 20 minutes. Measure absorbance at 475 nm.
[0086] The sample group was zeroed with blank control group 1, and the blank control group was zeroed with blank control group 3. The absorbance of the sample group was A, the absorbance of blank control group 1 was A1, the absorbance of blank control group 2 was A2, and the absorbance of blank control group 3 was A3. The inhibition rate was calculated as follows: Inhibition rate = [1-[(A-A1) / (A2-A3)] × 100%
[0087] The results are shown in Figure 5, which shows the inhibitory effects of THC, EGT, THC + THP, and THC + EGT + THP on tyrosinase activity. As shown in Figure 5, THC exhibited an approximately 77% inhibition rate against tyrosinase, while EGT exhibited an inhibition rate of 68%, THC + THP exhibited an inhibition rate of 86%, EGT + THP exhibited an inhibition rate of 79%, and EGT + THC + THP exhibited an inhibition rate of 92%. THC exhibited excellent tyrosinase inhibition, surpassing EGT. The combined effect of THC + EGT + THP was superior to that of THC + THP and EGT + THP.
[0088] The results show that the inhibition rate of the composition of the present invention on tyrosinase activity can reach about 80%, preferably about 90% or more.
[0089] Anti-glycemic test - testing the inhibitory effect of the composition of the present invention on AGEs
[0090] Bovine serum albumin (BSA) and D-ribose were placed together, and the formation of glycosylation products was observed in the case of the compositions of Examples 1 to 14 of the present invention and the composition of the comparative example.
[0091] A bovine serum albumin solution with a concentration of 1 mg / mL was dissolved in phosphate buffered saline (PBS), and incubated with D-ribose with a concentration of 10 mM and the above composition at 37° C. for 10 days.
[0092] It is known that final glycation end products emit light in the 420-600 nm range after excitation with light of wavelengths between 300 and 420 nm. Therefore, glycation was assessed by measuring the fluorescence of AGEs at λem = 450 nm after excitation at λex = 380 nm for each sample. Inhibition of glycation was determined by a decrease in fluorescence compared to samples treated with sugar alone.
[0093] Figure 6 shows the AGE inhibition rate of the composition of Example 12. As shown in Figure 6, the AGE inhibition rate of the control group was 33.8%, while the AGE inhibition rate of the composition of Example 12 was 56.4%. This indicates that the composition of Example 12 has excellent inhibitory activity against the formation of fluorescent AGEs. The composition of the present invention can achieve an AGE inhibition rate of approximately 50%, preferably at least 55%.
[0094] Moisturizing Test - Testing the Moisture Retention Effect of the Composition of the Invention
[0095] Preparation containing topical moisturizer:
[0096] A moisturizer containing the composition of Examples 1-14 of the present invention or the composition of the comparative example is prepared. The moisturizer may further contain one or more of the following ingredients: hyaluronic acid, vitamin E, cannabidiol, EGCG / green tea, polyhydroxy acid, glycolic acid, superoxide dismutase, tea tree oil, bakuchiol, grape seed oil, petrolatum or squalene or other suitable conventional moisturizer ingredients.
[0097] Clinical efficacy studies:
[0098] Thirty healthy female subjects aged 35-70 years with mild to moderate photoaging and Fitzpatrick skin types I-II were recruited for a clinical efficacy study. Inclusion and exclusion criteria were considered.
[0099] After enrollment, subjects will be randomly assigned to use a moisturizer containing the composition of Examples 1-14 of the present invention on the right or left side of the face, and a mild moisturizer or a moisturizer containing the composition of the comparative example on the opposite face. Neither the subjects nor the researchers will know the identity of the cream. The study coordinator will develop and maintain a blinded study. Subjects will be given a diary to record the daily use of the moisturizer, provide a return schedule, and be required to return to the research center at week 12. At each return (checkpoint), enrolled subjects will complete baseline efficacy and tolerability assessments on both sides of the face separately. Skin elasticity and corneal measurements will be measured and recorded from both sides of the face. In addition, at week 12 (study endpoint), both sides of the face will be wiped for microbiome analysis. Subject diaries will be checked for compliance and collected.
[0100] Efficacy evaluation:
[0101] Dermatologist investigators assessed efficacy parameters including fine lines, wrinkles, texture, radiance, brightness, smoothness, skin tone evenness, firmness, and pores. All assessments were performed at baseline and week 12 using a 5-point scale (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe). Each side of the face was assessed separately (data will be recorded in the table below).
[0102] Microbiome swab:
[0103] At baseline and week 12, both sides of the face will be swabbed for microbiome analysis. Each swab will generate two swabs, for a total of four swabs per subject. The swabs will be stored in a -80°C freezer until the end of the study and then shipped (on dry ice) to a commercial laboratory in Vancouver, Canada for quantitative microbiome analysis.
[0104] A facial swab will be obtained according to the following instructions: Step 1: Dip a fresh swab in molecular-grade, DNA-free water. Hold the skin site taut with one hand. Hold the swab with your other hand so the axis is parallel to the skin surface. Applying firm pressure, rub the swab back and forth 50 times (for 30 seconds), slowly rotating the swab as you rub. Step 2: Carefully place the swab back into the tube, ensuring that the swab, swab stick, and container do not touch any surface. Step 3: Place the tube in a biospecimen bag and freeze at -80°C until ready for shipment.
[0105] Table 1
[0106] Table 2
[0107] Figure 7 shows the colonization of Propionibacterium acnes. As shown in Figure 7, the colonization number of Propionibacterium acnes in the untreated group was 4.61×10 4 BioEcolia is a special saprophytic matrix with a colonization rate of 4.20×10 4 The number of colonization of Propionibacterium acnes in the solvent group (control group) was 4.01×10 4 The colonization number of Propionibacterium acnes by the composition of Example 12 was 3.89×10 4 It can be seen from this that the composition of Example 12 can reduce the colonization of Propionibacterium acnes.
[0108] Table 1 presents a tolerability assessment. As shown in Table 1, the composition of Example 12 was evaluated on each side of the subject's face and showed no statistically significant tolerability issues. Table 2 presents an efficacy assessment. As shown in Table 2, after 12 weeks of application of the composition of Example 12, the subject's skin texture, gloss, and brightness showed statistically significant improvements compared to baseline.
[0109] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Any person skilled in the art may make various changes, modifications, substitutions and variations to these embodiments without departing from the principles and purpose of the present invention. The scope of the present invention is defined by the claims and their equivalents.
Claims
1. A skin care composition, characterized in that The composition comprises a first active component and a second auxiliary component.
2. The skin care composition according to claim 1, characterized in that The skin care is one or more of alleviating skin photoaging, reducing skin fine lines and wrinkles, improving skin elasticity, improving skin firmness, improving skin gloss, brightness or texture, reducing or eliminating acne, alleviating skin inflammation, keeping skin moisturized, and improving or even skin tone.
3. The skin care composition according to claim 1 or 2, characterized in that The first active component is selected from one or more of the following: tetrahydrocurcumin, ergothioneine, phloretin, arbutin, resveratrol, vitamin C, dipotassium glycyrrhizinate, ceramide, aloe polysaccharide, cactus polysaccharide, astragalus polysaccharide, dendrobium polysaccharide, ginseng polysaccharide, fucoidan, small molecule hyaluronic acid, pearl powder, collagen, tea tree essential oil, thearubigin, salicylic acid, retinol, galactose, and carnosine; the second auxiliary component is selected from one or more of the following: tetrahydropiperine, laurocapram, PEG-75 shea butter glycerides, hydrogenated castor oil, glycerin, lauric acid, sucrose laurate, butylene glycol, polysorbate, hydroxyethyl cellulose, 1,2-pentanediol, and ethoxydiglycol.
4. The skin care composition according to any one of claims 1 to 3, characterized in that The weight ratio of the first active component to the second auxiliary component is 1:20 to 50:
1.
5. The skin care composition according to any one of claims 1 to 4, characterized in that The first active component is selected from one or more of the following: tetrahydrocurcumin, ergothioneine, phloretin, arbutin, resveratrol, vitamin C, dipotassium glycyrrhizinate, ceramide, cactus polysaccharide, astragalus polysaccharide, dendrobium polysaccharide, radix scutellariae polysaccharide, thearubigin, retinol, and carnosine.
6. The skin care composition according to any one of claims 1 to 5, characterized in that The first active component is selected from one or more of tetrahydrocurcumin and ergothioneine.
7. The skin care composition according to any one of claims 1 to 6, characterized in that The second auxiliary agent component is selected from one or more of tetrahydropiperine, laurocapram, and sucrose laurate.
8. The skin care composition according to any one of claims 1 to 7, characterized in that The second auxiliary component is selected from one or more of tetrahydropiperine and laurocapram.
9. The skin care composition according to any one of claims 1 to 8, characterized in that The first active component is tetrahydrocurcumin and / or ergothioneine, and the second auxiliary component is tetrahydropiperine.
10. The skin care composition according to any one of claims 1 to 9, characterized in that The weight ratio of the first active component to the second auxiliary component is 1:2 to 5:
1.
11. The skin care composition according to any one of claims 1 to 10, characterized in that The inhibition rate of the composition on tyrosinase activity reaches about 80%.
12. The skin care composition according to any one of claims 1 to 10, characterized in that The inhibition rate of the composition on TNF-α, IL-6 or IL-8 is greater than 20%.
13. The skin care composition according to any one of claims 1 to 10, characterized in that The composition can achieve an inhibition rate of about 50% for AGEs.
14. The skin care composition according to any one of claims 1 to 13, characterized in that The skin care composition is used for whitening, anti-inflammation, anti-sugar, moisturizing or tightening the skin.
15. Use of the skin care composition according to any one of claims 1 to 14 in the preparation of cosmetics.
16. A cosmetic, characterized in that: The cosmetic comprises the skin care composition according to any one of claims 1 to 14.
17. The cosmetic according to claim 16, characterized in that The cosmetics include lotions, essences, powders, emulsions, creams, gels, facial masks, and dressings.
18. The cosmetic according to claim 16 or 17, characterized in that: The weight ratio of the skin care composition in the cosmetic is 0.1-95%.
19. The cosmetic according to any one of claims 16 to 18, characterized in that: The weight ratio of the skin care composition in the cosmetic is 20-50%.